

SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway

Marjut Sarjomaa^{1, 2*}, Lien My Diep³, Chi Zhang^{3, 4}, Yngvar Tveten⁵, Harald Reiso⁶, Carina Thilesen⁷, Svein Arne Nordbø^{8, 9}, Kristine Karlsrud Berg¹⁰, Ingeborg Aaberge⁴, Neil Pearce¹¹, Hege Kersten^{12, 13}, Jan Paul Vandembroucke^{11, 14, 15}, Randi Eikeland^{16, 17}, Anne Kristin Møller Fell^{2, 17}

1 Department of Infection Control, Telemark Hospital Trust, Skien Norway, **2** Department of Community Medicine and Global Health and Society, University of Oslo, Norway, **3** Oslo Centre for Biostatistics and Epidemiology, Oslo, Norway, **4** Norwegian Institute of Public Health, Oslo, Norway, **5** Department of Clinical Microbiology, Telemark Hospital Trust, Skien, Norway, **6** The Norwegian National Advisory Unit on Tick-borne Diseases, Sørlandet Hospital Trust, Arendal, **7** Unilabs Laboratory Medicine, Skien, Norway, **8** Department of Medical Microbiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, **9** Norwegian University of Science and Technology, Trondheim, Norway **10** Department of Medical Microbiology, Sørlandet Hospital Trust, Kristiansand, Norway, **11** London School of Hygiene and Tropical Medicine, London, United Kingdom, **12** Department of Research, Telemark Hospital Trust, Norway, **13** School of Pharmacy, University of Oslo, Norway, **14** University of Leiden, Leiden, Netherlands, **15** University of Aarhus, Aarhus, Denmark, **16** Department of Health and Nursing Science, University of Agder, Grimstad, Norway, **17** Department of Occupational and Environmental Medicine, Telemark Hospital Trust, Skien, Norway

* Corresponding author:

Email: sarm@sthf.no (MS)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 **Abstract**

36 **Objectives:**

37 To assess total antibody levels against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS CoV-
38 2) spike protein up to 12 months after Coronavirus Disease (COVID-19) infection in non-vaccinated
39 individuals and the possible predictors of antibody persistence.

40 **Methods:**

41 This is a prospective multi-centre longitudinal cohort study.

42 **Participants**

43 The study included SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) positive and negative
44 participants in South-Eastern Norway from February to December 2020. Possible predictors of SARS-
45 CoV-2 total antibody persistence was assessed. The SARS-CoV-2 total antibody levels against spike
46 protein were measured three to five months after PCR in 391 PCR-positive and 703 PCR-negative
47 participants; 212 PCR-positive participants were included in follow-up measurements at 10 to 12
48 months. The participants completed a questionnaire including information about symptoms,
49 comorbidities, allergies, body mass index (BMI), and hospitalisation.

50 **Primary outcome**

51 The SARS-CoV-2 total antibody levels against spike protein three to five and 10 to 12 months after
52 PCR positive tests.

53 **Results:**

54 SARS-CoV-2 total antibodies against spike protein were present in 366 (94%) non-vaccinated PCR-
55 positive participants after three to five months, compared with nine (1%) PCR-negative participants.
56 After 10 to 12 months, antibodies were present in 204 (96%) non-vaccinated PCR-positive
57 participants. Of the PCR-positive participants, 369 (94%) were not hospitalised. The mean age of the
58 PCR-positive participants was 48 years (SD 15, range 20-85) and 50% of them were male. BMI \geq 25
59 kg/m² was positively associated with decreased antibody levels (OR 2.34, 95% CI 1.06 to 5.42).
60 Participants with higher age and self-reported initial fever with chills or sweating were less likely to
61 have decreased antibody levels (age: OR 0.97, 95% CI 0.94 to 0.99; fever: OR 0.33, 95% CI 0.13 to
62 0.75).

63 64 **Conclusion**

65 Our results indicate that the level of SARS-CoV-2 total antibodies against spike protein persists for
66 the vast majority of non-vaccinated PCR-positive persons at least 10 to 12 months after mild COVID-
67 19.

68 Key words: Covid-19, SARS-CoV-2, humoral immune response, antibodies

69

70

71 Introduction

72 Since the initial outbreak of COVID-19 was reported in Wuhan in December 2019, over 304 million
73 people have been infected worldwide, with over 5.4 million deaths reported by the World Health
74 Organization (WHO) as of 11th January 2022 [1]. The first wave of the pandemic in Norway peaked in
75 March 2020. The second wave started in the autumn of 2020 and the third wave in February 2021.
76 The estimated seroprevalence of SARS CoV-2 antibodies in Norway was 0.6% in the late summer of
77 2020 and increased to 3.2% in January 2021, after the second wave [2].

78 The impact of SARS-CoV-2 on human health in individuals and populations depends on multiple
79 factors such as the level of healthcare, diagnostics, therapeutics, social distancing measures such as
80 lockdowns, face masks, working from home, and the availability and coverage of vaccines to control
81 the disease. Understanding the cellular and humoral immunity to COVID-19 is necessary to assess the
82 future course of the pandemic. There is still insufficient data regarding the long-term persistence of
83 antibodies and the level of protective immunity, especially in patients who underwent mild infections
84 and those who were not hospitalised [3-9]. Hence, there is a need for studies on antibody kinetics to
85 improve our understanding of humoral immunity following COVID-19 infections.

86 The gold standard for antibody test assays has not been determined, and numerous immunoassays
87 have been developed [10]. IgG antibodies against SARS-CoV-2 are highly sensitive markers 7–14 days
88 after symptom onset [8, 11]. Antibodies are detected in 90% of individuals after two weeks and are
89 highly correlated with neutralising antibodies [8, 12]. High sensitivity and specificity are important for
90 all serological assays, and the specificity of an antibody test might be an issue when the infection
91 prevalence is low [13]. Some smaller studies early in the pandemic showed that antibodies declined
92 within a few months after infection [14-16]. Antibody levels against the nucleocapsid protein have
93 been shown to decline more rapidly than antibodies against the spike protein [12]. Furthermore, the
94 kinetics and protective immunity between anti-nucleocapsid and anti-spike antibodies may differ
95 [17]. Data from large, systematic, and quantitative follow-up studies of antibodies for longer than six
96 to eight months are limited [18, 19].

97 The study of antibody persistence is still important, despite vaccination, as antibody longevity during
98 an ongoing pandemic is of scientific interest, as well as being particularly relevant for providing
99 correct and informed vaccination strategies to those who have had an infection. However, there is
100 still a lack of knowledge regarding the longevity of protective immunity.

101 Our aim was to assess the SARS-CoV-2 total antibody levels against spike protein up to 12 months
102 after COVID-19 infection in non-vaccinated individuals, and identify possible predictors for antibody
103 persistence [20].

104

105 Materials and methods

106 Study design and setting

107 Adults aged 18 years or older residing in South-Eastern Norway (Agder and Telemark counties) were
108 considered eligible for inclusion in the study. Participants were recruited from all hospitals in the
109 region, municipality laboratories, and test centres between February 28 and December 17, 2020. For
110 each PCR-positive (PCR+) participant, we selected two PCR- negative (PCR-) participants matched by
111 residency and time for the PCR test. The main reason for including PCR- negative participants was the
112 possibility for further studies assessing risk factors, reinfections and vaccine responses.

113 Participants who did not consent or were unable to answer a questionnaire (Norwegian language)
114 were excluded. COVID-19 vaccination was introduced in January 2021, and post-vaccine samples
115 were excluded in this study.

116 The official Norwegian testing criteria for SARS-CoV-2 changed over time but were the same for the
117 matched PCR+ and PCR- participants. In the first wave of the pandemic, PCR testing was restricted to
118 patients with symptoms. In the second wave, PCR testing was also applied to close contacts and
119 asymptomatic persons during outbreaks. All participants were invited to the sampling of antibodies
120 and were asked to fill in the self-reporting questionnaire simultaneously, three to five months (time
121 point 1=T1) after the PCR test. The group of non-vaccinated PCR+ participants were invited for
122 follow-up 10 to 12 months (time point 2 =T2) after the PCR test.

123 Participation was voluntary, and participants were not offered any financial incentives.

124 **Data sources/measurement**

125 **Questionnaire**

126 Questions from the Norwegian Health Institute COVID-19 questionnaire and the validated Telemark-
127 study questionnaire were used [21-24], in addition to questions provided by the study group. A user
128 representative was involved in the process of piloting the questionnaire. Questions are shown in S1
129 Table.

130 The questionnaire consisted of questions about demographic data, income, education, smoking
131 habits, hospitalisation, and comorbidities such as asthma and chronic obstructive pulmonary disease
132 (COPD), other lung diseases, cancer, heart disease, diabetes, hypertension, musculoskeletal disease,
133 any other disease and pollen allergy. Questions about symptoms included the presence or absence of
134 cough, runny nose, stuffy nose, sore throat, dyspnoea, headache, fever with chills or sweating,
135 abdominal pain, nausea, diarrhoea, impaired sense of smell and taste, myalgia, and dizziness.
136 Questions regarding fatigue and reinfection were also included.

137 Self-reported vaccination data were available and checked against data from the National
138 Immunisation Register (SYSVAK). Additional demographic data (age, sex, and time and place for
139 SARS-CoV-2 PCR) were also registered.

140 **Laboratory methods**

141 Venous blood samples were obtained at recruitment, three to five months after the PCR test (T1),
142 and again after 10-12 months (T2). All serum samples were prepared from whole blood following
143 centrifugation for 10 min at a minimum of 1800 g at room temperature and stored at -80 °C until
144 further analysis. Total immunoglobulin levels were analysed at Telemark Hospital using the Siemens
145 Advia Centaur XP SARS-CoV-2 Total assay for the qualitative detection of total antibodies (IgM and
146 IgG) in human serum. On a large panel of blood samples, the Siemens assay achieved a sensitivity
147 and specificity of at least 98% [10]. The assay is a fully automated 1-step antigen sandwich
148 immunoassay using acridinium ester chemiluminescent technology and recombinant SARS-CoV-2 S 1
149 receptor binding domain (RBD) antigen. The total antibody ranged from 0 to 9.99, and ≥ 10 was the
150 upper limit of the assay. The threshold for reactivity was ≥ 1.0 Index. To make it possible to interpret
151 changes in antibody levels, antibody levels were categorised into four categories: negative (0-0.79),
152 low (0.80-1.99), intermediate (2.00-9.99), and high (≥ 10).

153 To reduce the possibility of false positive results, low antibody levels between 0.80 and 1.99 Index
154 value were reanalyzed at St. Olavs Hospital in Trondheim using the Elecsys Cobas SARS-CoV-2 total
155 antibody test (Roche) and BioPlex 2200 SARS-CoV-2 IgG Panel (Bio-Rad).

156 Ethics approval and consent to participate

157 All participants provided written informed consent before inclusion. The Study was approved by the
158 Regional Committee for Medical and Health Research Ethics of South East Norway A (ID 146469), the
159 Norwegian Centre for Research Data (NSD), and the Data Protection Officers in the participating
160 hospitals.

161

162 Statistical analysis

163 Mean, standard deviation (SD), medians, interquartile ranges (IQR), and minimum and maximum
164 values were reported for continuous data as appropriate. Categorical data were reported as
165 frequencies and percentages.

166 The difference between the observed antibody values at T1 and T2 were calculated. The changes that
167 were greater than the maximum level of 10 Index could not be quantified due to the limitations of
168 the assay. Hence, for further analysis, the participants were categorised into four antibody groups:
169 decreased, unchanged, increased, and maximum level ≥ 10 . An increase or decrease of at least 20%
170 in antibody values from T1 to T2 was defined as a significant change; otherwise, the participant was
171 assigned to the unchanged antibody group. Chi-squared and Fisher's exact tests were used to
172 examine differences in proportions between the decreased antibody group and the other groups
173 (unchanged, increased, and maximum antibody level ≥ 10) for binary variables. For continuous and
174 ordinal variables, the Kruskal-Wallis test and the One-Way Anova was used to study the difference.
175 Total symptom and comorbidity scores were calculated by adding the number of symptoms or
176 comorbidities for each participant, and used instead of single variables in the multivariate analysis.

177 Logistic regression models were used to study the possible predictors for changes in antibody levels.
178 Univariate analysis was performed for each predictor, adjusting for age and sex. Then, a multivariate
179 analysis including all predictors was performed, and the standard error of the effect estimate was
180 compared to that of the corresponding univariate analysis for each predictor to check for collinearity.
181 Odds ratio (OR) was reported with 95% confidence intervals (CI) for association between decreased
182 antibody level and predictors. The analyses were performed with IBM SPSS 27 for Windows (IBM
183 Corp. Released 2020. IBM SPSS Statistics for Windows version 27.0. Armonk, NY: IBM Corp), Stata/SE
184 16.1 for Windows and R (version 4.2).

185

186 Results

187 Between February 28 and December 17, 2020, 656 PCR+ participants and 923 PCR- controls matched
188 in time and location to the PCR+ participants were eligible. In summary, 232 PCR+ participants and 92
189 PCR-participants did not meet the inclusion criteria. Nine PCR+ and 16 PCR- participants were
190 vaccinated prior to the first antibody sampling and were excluded from the study. The number of
191 individuals assessed for eligibility and individuals included in the study is shown in **Fig 1**.

192 Fig 1. Flow chart for the study.

193 The demographics of the study population by baseline are presented in **Table 1**.

194

195 **Table 1. Characteristics of the PCR positive (PCR+) and PCR negative (PCR-) participants at the first**
196 **antibody test (T1).**

Characteristics	Total (N = 1094)	PCR+ (N=391)	PCR- (N= 703)
	N (%)	N (%)	N (%)

Age in years, mean (SD)	47.5 (14.6)	47.9 (15.0)	47.3 (14.3)
N (range)	1094 (19-98)	391 (20-85)	703 (19-98)
BMI in kg/m², median (IQR)	26.6 (23.2-29.1)	26.4 (23.2-28.7)	26.8 (23.3-29.3)
N (range)	1057 (15.7-65.6)	374 (16-43)	683 (16-66)
BMI in kg/m² ≥ 25	598 (56.6)	206 (55.1)	392 (57.4)
Gender, males	435 (39.8)	196 (50.1)	239 (34.0)
Income			
<500 000 NOK ^a	216 (20.4)	68 (17.4)	148 (21.1)
500 000-1 000 000 NOK	474 (44.7)	162 (41.4)	312 (44.4)
≥ 1 000 000 NOK	365 (34.6)	137 (35.0)	228 (32.4)
Education			
Primary & secondary school	116 (10.6)	40 (10.2)	76 (10.8)
High school & certificate	362 (33.1)	146 (37.3)	216 (30.7)
University less than 4 years	342 (31.3)	128 (32.7)	214 (30.4)
University > 4 years	255 (23.3)	66 (16.9)	189 (26.9)
Smoking			
Non-smoker	527 (56.0)	213 (61.5)	314 (52.8)
Past smoker	302 (32.1)	103 (29.8)	199 (33.4)
Occasional and daily smoker	112 (11.9)	30 (8.7)	82 (13.8)
Comorbidity			
Asthma	195 (17.8)	61 (15.6)	134 (19.1)
COPD	34 (3.1)	7 (1.8)	27 (3.8)
Other chronic lung disease	44 (4.0)	16 (4.1)	28 (4.0)
Cancer	37 (3.4)	7 (1.8)	30 (4.3)
Heart disease	48 (4.4)	16 (4.1)	32 (4.6)
Diabetes	47 (4.3)	20 (5.1)	27 (3.8)
Hypertension	110 (10.1)	39 (10.0)	71 (10.1)
Musculoskeletal disease	63 (5.8)	17 (4.3)	46 (6.5)
Any other disease	194 (17.7)	55 (14.1)	139 (19.8)
No disease	554 (50.6)	211 (54.0)	343 (48.8)
Pollen allergy	298 (27.2)	96 (24.6)	202 (28.7)
Symptoms			
Cough	511 (46.7)	181 (46.3)	330 (46.9)
Running nose	470 (43)	124 (31.7)	346 (49.2)
Stuffy nose	416 (38.0)	123 (31.5)	293 (41.7)

Sore throat	531 (48.5)	161 (41.2)	370 (52.6)
Pain in swallowing	239 (21.8)	53 (13.6)	186 (26.5)
Dyspnoea	417 (38.1)	296 (50.1)	221 (31.4)
Headache	565 (51.6)	250 (63.9)	315 (44.8)
Fever	503 (46.0)	254 (65.0)	249 (35.4)
Fever with chills or sweating	311 (28.4)	163 (41.7)	148 (21.1)
Abdominal pain, nausea or diarrhoea	250 (22.9)	117 (29.9)	133 (18.9)
Impaired sense of smell or taste	360 (32.9)	260 (66.5)	100 (14.2)
Myalgia	459 (42.0)	227 (58.1)	232 (33.0)
Dizziness	318 (29.1)	167 (42.7)	151 (21.5)
Fatigue, moderate and serious^b	132 (12.8)	104 (26.6)	28 (4.0)

^a One NOK= 0.096 Euro

^b Fatigue categories:1=no, 2=light, 3=moderate, 4 = serious

SD: Standard deviation

IQR: Interquartile range

197 Except for asthma (18%), the prevalence of self-reported comorbidities was low for all participants.
198 However, PCR+ participants reported more symptoms such as dyspnoea, headache, fever with chills
199 or sweating, abdominal pain, nausea or diarrhoea, impaired sense of taste and smell, myalgia, and
200 dizziness compared to the PCR- participants. In contrast, PCR- participants reported more nasal
201 symptoms (runny/stuffy nose), sore throat, and pain upon swallowing compared to the PCR+
202 participants. Coughing was similar in both groups. Self-reported moderate or serious fatigue was
203 more frequent among PCR+ than PCR- participants. Only 22 (6%) of the PCR+ participants were
204 hospitalised due to COVID-19. There were no self-reported reinfections during the study period.

205 The duration and changes in total antibody levels against the SARS-CoV-2 spike protein are shown in
206 **Table 2.**

207

208 **Table 2. The duration and changes in total antibody levels against the SARS-CoV-2 spike protein**
209 **measured with Index value three to five months (T1) and 10 to 12 months (T2) after PCR test for**
210 **PCR positive (PCR+) and PCR negative (PCR-) participants.**

Time point to antibody measurement	Antibody level category in Index value	Total	PCR+	PCR-
		N (%)	N (%)	N (%)
T1 antibody	0.00 - 0.79	718 (65.0)	25 (6.4)	693 (98.7)
T1 antibody	0.80 - 1.99	27 (2.5)	26 (6.6)	1 (0.1)
T1 antibody	2.00 - 9.99	135 (12.3)	132 (33.8)	3 (0.4)

T1 antibody	≥10	213 (19.5)	208 (53.2)	5 (0.7)
T2 antibody	0.00 - 0.79		8 (3.8)	
T2 antibody	0.80 - 1.99		14 (6.6)	
T2 antibody	2.00 - 9.99		63 (29.7)	
T2 antibody	≥10		127 (59.9)	
Decreased antibody level, T1 to T2			39 (18.4)	
Unchanged antibody level, T1 to T2			35 (16.5)	2 ^a
Increased antibody level, T1 to T2			25 (11.8)	1 ^a
Antibody level ≥ 10 at T1 & T2			113 (53.3)	

211 ^a Percent is not reported due to low number of participants with antibodies in this group.

212

213 Among the PCR+ participants, 366 (94%) had total levels of antibodies ≥ 0.8, and 208 (53%) had total
214 levels of antibodies at the upper limit of quantification three to five months after the positive PCR
215 test. Twenty participants with uncertain antibody values were reanalysed; three of them showed no
216 antibodies in the secondary test and were defined as false positives in the first test. Among the 212
217 participants with antibody measurements at both T1 and T2, 204 (96%) had antibodies ≥ 0.8, and 113
218 (53%) had values above the upper limit of quantification of the total antibody at both measurements.
219 The time between PCR and antibody measurements is shown in S2 Table.

220 The distribution of variables in PCR+ participants with decreased, unchanged, increased and antibody
221 levels ≥ 10 at time points T1 and T2 are shown in **Table 3**.

222

223 **Table 3. The distribution of variables in PCR+ participants with detectable antibodies grouped as**
224 **decreased, unchanged, increased, and antibody level ≥ 10 at time point T1 and T2.**

Variable of interest^a	Decreased N=39	Unchanged and increased N=62	Antibody ≥ 10 N=114	p-value^b
	N (%)	N (%)	N (%)	
Age in years, mean (SD)	44.5 (12.7)	47.5 (13.8)	52.6 (14.6)	0.003
N (range)	39 (22-78)	62 (21-81)	114 (21-85)	
BMI ≥ 25.0 kg/m²	26 (68.4)	24 (40.0)	65 (59.1)	0.011
Gender, males	20 (51.3)	29 (46.8)	65 (57.0)	0.417
Income				
<500 000 NOK ^c	8 (21.6)	7 (11.5)	13 (11.8)	0.605
500 000-1 000 000 NOK	11 (29.7)	22 (36.1)	49 (44.5)	
≥ 1 000 000 NOK	18 (48.6)	32 (52.5)	48 (43.6)	

Education				
Primary, secondary, and high school	17 (44.7)	23 (37.7)	51 (45.1)	0.588
University less than 4 years	14 (36.8)	24 (39.3)	41 (36.3)	
University more than 4 years	7 (18.4)	14 (23.0)	21 (18.6)	
Smoking				
Non-smoker	28 (80.0)	36 (64.3)	57 (53.8)	0.080
Past smoker	5 (14.3)	15 (26.8)	39 (36.8)	
Occasional and daily smoker	2 (5.7)	5 (8.9)	10 (9.4)	
Comorbidity				
Asthma	5 (13.5)	9 (14.8)	20 (17.9)	0.772
COPD	0	1 (1.6)	4 (3.7)	0.583
Other chronic lung disease	1 (2.6)	2 (3.3)	4 (3.5)	1.000
Cancer	1 (2.6)	1 (1.6)	1 (0.9)	0.753
Heart disease	2 (5.3)	3 (4.9)	7 (6.2)	1.000
Diabetes	0	1 (1.6)	10 (8.9)	0.040
Hypertension	2 (5.3)	2 (3.3)	16 (14.2)	0.048
Musculoskeletal disease	2 (5.3)	2 (3.3)	4 (3.5)	0.790
Any other disease	7 (18.4)	6 (9.8)	7 (18.4)	0.471
Comorbidity sum, mean (SD)	0.5 (0.7)	0.4 (0.7)	0.7 (0.9)	0.100
Pollen allergy	6 (16.2)	15 (24.6)	30 (26.8)	0.504
Symptoms by the time of diagnosis of covid-19				
Cough	15 (42.9)	26 (47.3)	62 (61.4)	0.083
Running nose	13 (37.1)	17 (30.4)	29 (28.7)	0.646
Stuffy nose	15 (42.9)	18 (32.1)	30 (28.8)	0.309
Sore throat	14 (41.2)	22 (39.3)	48 (47.1)	0.607
Pain upon swallowing	4 (11.4)	7 (12.5)	15 (14.6)	0.921
Dyspnoea	21 (60.0)	30 (53.6)	66 (64.7)	0.390
Headache	28 (82.4)	43 (76.8)	70 (68.0)	0.197
Fever	24 (68.6)	42 (75.0)	82 (79.6)	0.400
Fever with chills or sweating	10 (25.6)	24 (38.7)	58 (50.9)	0.017
Abdominal pain, nausea or diarrhoea	14 (40.0)	13 (23.6)	34 (33.7)	0.231
Impaired sense of smell or taste	29 (82.9)	41 (73.2)	80 (77.7)	0.561
Myalgia	21 (60.0)	29 (52.7)	73 (70.9)	0.068
Dizziness	14 (40.0)	25 (45.5)	56 (54.9)	0.245
Number of symptoms, mean (SD)	6.3 (2.7)	6.0 (2.2)	6.8 (2.5)	0.177
Fatigue^e, moderate and serious	7 (20.0)	10 (17.0)	42 (38.5)	0.006

225 ^a Table 3 includes 212 PCR+ participants and three PCR- participants with detectable antibodies.

226 ^b P-value for comparison between decreased and the group (unchanged, increased, and antibody ≥ 10).

227 ^c NOK= Norwegian kroner (One NOK= 0.096 Euro)

228 ^d COPD= Chronic obstructive pulmonary disease

229 ^e Fatigue categories: 1=no, 2=light, 3=moderate, 4 = serious.

230

231 Univariate and multivariate regression analyses were performed to assess the possible predictors for
232 antibody levels after 10-12 months, and to compare the group with decreased antibody levels with
233 the other groups (increased, unchanged, and antibody ≥ 10), as shown in **Table 4**.

234

235 **Table 4. Possible predictors for decreased antibodies after 10 to 12 months compared with**
236 **increased, unchanged and antibody ≥ 10 using logistic regression.**

		Univariate analysis adjusted for age and sex				Multivariate analysis fully adjusted			
		OR	2.5%	97.5%	p- value	OR	2.5%	97.5%	p- value
Age (numeric)		0.97	0.94	0.99	0.01	0.97	0.93	1.00	0.030
Gender	Male	0.92	0.46	1.85	0.81	0.77	0.32	1.85	0.563
BMI kg/m²	≥ 25	2.34	1.06	5.42	0.04	2.15	0.9	5.41	0.093
Education	Below University	/				/			
	University < 4 years	0.79	0.35	1.76	0.57	0.60	0.23	1.50	0.278
	University ≥ 4 years	0.83	0.30	2.15	0.71	0.50	0.14	1.62	0.265
Income Norwegian kroner	< 500 000	/				/			
	500 000 - 1000 000	0.47	0.16	1.41	0.17	0.61	0.19	2.12	0.425
	> 1000 000	0.62	0.23	1.77	0.35	0.82	0.25	2.87	0.743
Smoking	Non-smoker	/				/			
	Past smoker	0.37	0.12	0.96	0.06	0.34	0.11	0.93	0.049
	Daily and occasional smoker	0.37	0.06	1.46	0.21	0.37	0.05	1.62	0.240
Symptoms									
Symptoms score (numeric)	/	1.0	0.85	1.08	0.48	0.97	0.84	1.11	0.612
Dyspnoea	No	/				/			
	Yes	1.02	0.50	2.08	0.97	not included			
Fever with chills/sweating	No	/				/			
	Yes	0.33	0.13	0.75	0.01	not included			
Abdominal pain/diarrhoea/nausea	No	/				/			
	Yes	1.69	0.78	3.59	0.18	not included			
Loss of smell and taste	No	/				/			
	Yes	1.17	0.53	2.74	0.71	not included			

Comorbidity score	/	1.02	0.61	1.62	0.93		1.08	0.61	1.84	0.774
-------------------	---	------	------	------	------	--	------	------	------	-------

237

238 Discussion

239 Total antibodies against the SARS-CoV-2 spike protein were detectable in 96% of the participants up
240 to 12 months after a positive PCR test. BMI ≥ 25 kg/m² was positively associated with decreased
241 antibody level (OR 2.34, 95% CI 1.06 to 5.42). Participants with higher age and self-reported initial
242 fever with chills or sweating were less likely to have decreased antibody levels (age: OR 0.97, 95% CI
243 0.94 to 0.99; fever: OR 0.33, 95% CI 0.13 to 0.75). There was no association between antibody
244 persistence and gender. Past smoking history was negatively associated with decreased antibody
245 levels (OR 0.37, 95% CI 0.12 to 0.96) in our study, but this finding should be interpreted with caution
246 because there were few smokers.

247

248 Among the PCR negative participants, nine had total antibodies ≥ 0.8 at T1, and after initial
249 symptoms, they did not report reinfection between the time of the PCR test and the antibody
250 measurement. The most likely explanation is that they had COVID-19 and a false-negative PCR test, a
251 test taken incorrectly or a low virus level at the time of the test.

252 We did not detect any self-reported reinfections during the study period. A recent large prospective
253 multicentre cohort study from all the regions in England showed an 84% lower risk of reinfection
254 after seven months of follow-up post SARS-CoV-2 infection among healthcare workers (HCWs) with
255 positive antibodies tested with a range of assays [25]. The correlation between antibody levels and
256 protective immunity remains unclear.

257 The results for antibody persistence after 10 to 12 months in our study were in accordance with
258 those of several studies with a shorter follow-up time [9, 19, 21]. A seroprevalence study from
259 Iceland reported that pan-IgG antibodies did not decline within four months after the diagnosis of
260 SARS-CoV-2 infection in (91% of the included subjects [26]. Furthermore, a study from the USA
261 initially assessing 188 SARS-CoV-2 PCR-positive subjects showed durable spike IgG titres at six to
262 eight months after symptom onset for 36 out of 40 individuals at follow-up [19]. Recently, a peer-
263 reviewed study by Turner et al. showed that in a follow-up of 42 COVID-19 convalescent patients,
264 spike IgG antibodies were detectable at least 11 months after infection [9]. A recent cross-sectional
265 study from USA showed antibodies at median 8.7 months after COVID-19 diagnosis [27].

266 Other studies that used different assays have shown contradictory results for antibody persistence
267 with rapidly declining antibodies [15, 22]. There is a large heterogeneity in the test performance of
268 different immunoassays [28]. Some studies have investigated nucleocapsid antibodies, which have
269 been shown to decline faster than spike antibodies [29, 30]. A study of 97 participants in Korea
270 showed declining nucleocapsid IgG antibody levels with reduction rates of 46% from six weeks to six
271 months after diagnosis [29].

272 Lower persistence of IgG antibodies has been reported in asymptomatic compared to symptomatic
273 COVID-19 patients two to three months after the PCR-confirmed SARS-CoV-2 infection in a study of
274 37 participants from China [15]. Accordingly, a study from Italy showed a declining antibody response
275 with three different serological assays in 20 individuals with mild symptoms two months after the
276 initial symptom onset [28].

277 Many of the published studies on antibody levels have focused on specific populations such as HCWs
278 or hospitalised patients, and these results may not be representative of the general population [18,
279 31]. In a Swedish longitudinal seroprevalence study among 355 HCWs, 98% had antibodies against

280 spike protein at least four months post infection [30]. Antibodies were lower among HCWs than
281 among 59 hospitalized COVID-19 patients. Most HCWs had mild symptoms prior to inclusion in the
282 study.

283 Previous studies reporting factors associated with longevity of antibodies show a decline in
284 antibodies or seronegativity among asymptomatic patients or patients with mild symptoms. Van
285 Elslande et al. showed in their study that SARS-CoV-2 anti-nucleocapsid antibody levels were
286 significantly lower in those with asymptomatic and mild SARS-CoV-2 infection than in those with
287 severe disease, and that 61% of them became seronegative within 6 months post-PCR [32]. Hence,
288 our findings of up to 12 month persistence in 96% of mainly non-hospitalised persons with mild
289 symptoms are interesting. However the difference may be explained by the use of antibody against
290 spike protein instead of nucleocapsid.

291 Our study agrees with other studies concerning the association between age and antibody
292 persistence. In a 180 days follow-up study of 164 infected patients, Chia et al. found that antibody
293 persistence was associated with disease severity, older age, and more comorbidities compared with
294 those who had rapidly declining antibodies, although a greater proportion (11 of 19) of
295 asymptomatic individuals were in the seronegative group [33].

296 BMI ≥ 25 kg/m² was strongly associated with decreased antibody level in our study. This was not in
297 agreement with a recent Norwegian study that showed the severity of initial illness, older age, and
298 higher BMI were independently associated with increased antibody levels two months after infection
299 [34]. A large prospective cohort study from the United States showed homogenous immune activity
300 across BMI categories [35]. A large retrospective study from Israel showed that the peak level of
301 neutralising antibodies was associated with obesity, with the highest level in patients who were
302 severely obese [36]. The study did not include any follow-up antibodies. A study from Turkey showed
303 no effect of BMI on antibody titres, but the sample size was small and the follow-up period was only
304 60 days [37]. Nevertheless, obesity was a risk factor for COVID-19 infection severity in many studies
305 as shown in a meta-analysis of 42 studies [38]. It is possible that the diversity of the results of the
306 association between BMI and antibody persistence after COVID-19 infection is dependent on disease
307 severity.

308 There was no association between gender, income, education, and antibody persistence in our study.
309 Socioeconomic differences in Norway are relatively small, and most of the included participants were
310 from the middle class and above, as reflected in the high levels of education and income among the
311 participants.

312 Our study has several strengths and limitations. A strength of our study is the relatively large and
313 unselected study cohort recruited during the first and second pandemic waves in Norway. The time
314 for the antibody test was related to the PCR test, and not the onset of symptoms. Another strength is
315 the longitudinal design with a relatively long follow-up time. Validated serology assays were used,
316 and the participants answered the questionnaire on the same day as the serum sampling.

317
318 A limitation of our study is that changes in antibody levels above the assay's upper limit value 10
319 Index could not be determined, but it is probably in the group with low antibody levels that
320 significant changes will appear. Direct comparison of the current study's results with those of other
321 studies is difficult because assays targeting different antigens are used in the available studies [10].
322 Further, differences in study populations, severity of illness, and frequency of antibody sampling
323 make comparisons across studies challenging [31]. In our study, the same assay was used for all
324 participants and as a quality control, all PCR- participants with detectable antibodies and all PCR+
325 participants with low levels of antibodies were retested with a second assay. Using two different

326 assays was considered useful in low seroprevalence countries like Norway because of the possibility
327 of false-positive tests [14].

328

329 The use of a self-reported questionnaire may be considered a limitation of the study because of
330 recall bias. Further, the participants might not understand the questions as intended, and the
331 response rates differed for the questions used. However, all questions included in the questionnaire
332 were chosen from validated or frequently used questionnaires [21-24, 39].

333 Measurements of cellular immunity and neutralising antibodies were not feasible in this study, but it
334 is important to consider when evaluating the immune status post COVID-19 [19]. T-cell responses in
335 SARS-CoV-2 patients have been detected in recovered patients without an antibody response [40].
336 Early T-cell response may have an important role in protection against reinfections and recovering
337 from SARS-COV-2 infection [41]. T-cell immunity is robust, and its memory might be longer-lasting
338 [42].

339

340 Conclusion

341 In this Norwegian study of mainly non-hospitalized SARS CoV-2 PCR+ participants, 96% had high
342 antibody levels and no reported reinfections were detected one year after the PCR tests. BMI \geq 25
343 kg/m² was positively associated with decreased antibody levels (OR 2.34, 95% CI 1.06 to
344 5.42). Participants with higher age and self-reported initial fever with chills or sweating were less
345 likely to have decreased antibody levels (age: OR 0.97, 95% CI 0.94 to 0.99; fever: OR 0.33, 95% CI
346 0.13 to 0.75). We did not detect an association between antibody persistence and gender. Our
347 results indicate that the level of antibodies following mild COVID-19 persists for at least 10 to 12
348 months.

349

350 Acknowledgements

351 We thank Sølvi Noraas (Department of Clinical Microbiology, Kristiansand, Norway) for organising of
352 the serological analysis in Agder. The authors are deeply grateful to Trude Belseth Sanden, Astrid
353 Bjørkeid, June Bakstevold, Gølin Finkenhagen Gundersen, Emile van Gelderen, Elin Skjørsvold
354 Christensen, Louise Myrland, Signe Seljåsen, Mona Brekke, Siv Stigen, Anne Cecilie Tveiten, Oda
355 Eikeland Myrnes and Siri Cathrine Rølland for their essential assistance for data collection and
356 analysis. The authors would like to express their gratitude to all the participants in this study and to
357 the patient representatives.

358

359 References

- 360 1. WHO. Weekly epidemiological Update and Weekly Operational Update.
361 WHO; 2021. Available from: [https://www.who.int/publications/m/item/weekly-epidemiological-
362 update-on-covid-19---11-january-2022](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---11-january-2022)
- 363 2. FHI. Seroprevalence-of-sars-cov-2-in-the-norwegian-population. Available from:
364 [https://www.fhi.no/en/publ/2021/seroprevalence-of-sars-cov-2-in-the-norwegian-population-
365 measured-in-residu/](https://www.fhi.no/en/publ/2021/seroprevalence-of-sars-cov-2-in-the-norwegian-population-measured-in-residu/)
- 366 3. Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, et al. Antibody response
367 to SARS-CoV-2 infection in humans: A systematic review. PLOS ONE. 2020; 15: e0244126. doi:
368 [10.1371/journal.pone.0244126](https://doi.org/10.1371/journal.pone.0244126).

- 369 4. Khoshkam Z, Aftabi Y, Stenvinkel P, Paige Lawrence B, Rezaei MH, Ichihara G, et al. Recovery
370 scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection. J
371 Adv Res. 2021;31: 49–60. doi: [10.1016/j.jare.2020.12.013](https://doi.org/10.1016/j.jare.2020.12.013).
- 372 5. Føns S, Krogfelt KA. How can we interpret SARS-CoV-2 antibody test results? Pathog Dis.
373 2021;79. doi: [10.1093/femspd/ftaa069](https://doi.org/10.1093/femspd/ftaa069).
- 374 6. Arkhipova-Jenkins I, Helfand M, Armstrong C, Gean E, Anderson J, Paynter RA, et al. Antibody
375 response After SARS-CoV-2 infection and implications for immunity: A rapid living review. Ann Intern
376 Med. 2021; 174: 811–821. doi: [10.7326/M20-7547](https://doi.org/10.7326/M20-7547).
- 377 7. Crawford KHD, Dingsen AS, Eguia R, Wolf CR, Wilcox N, Logue JK, et al. Dynamics of
378 neutralizing antibody titers in the months after SARS-CoV-2 infection. J Infect Dis. 2020. doi:
379 [10.1093/infdis/jiaa618](https://doi.org/10.1093/infdis/jiaa618)
- 380 8. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Persistence and decay of
381 human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19
382 patients. Sci Immunol. 2020; 5. doi: [10.1126/sciimmunol.abe0367](https://doi.org/10.1126/sciimmunol.abe0367).
- 383 9. Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, et al. SARS-CoV-2 infection
384 induces long-lived bone marrow plasma cells in humans. Nature. 2021; 595: 421–425. doi:
385 [10.1038/s41586-021-03647-4](https://doi.org/10.1038/s41586-021-03647-4).
- 386 10. National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five
387 immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. 2020; 20:
388 1390–1400. doi: [10.1016/S1473-3099\(20\)30634-4](https://doi.org/10.1016/S1473-3099(20)30634-4).
- 389 11. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2
390 in patients with COVID-19. Nat Med. 2020; 26: 845–848. doi: [10.1038/s41591-020-0897-1](https://doi.org/10.1038/s41591-020-0897-1).
- 391 12. Lumley SF, Wei J, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, et al. The duration,
392 dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. Clin
393 Infect Dis. 2021; 73: e699–e709. doi: [10.1093/cid/ciab004](https://doi.org/10.1093/cid/ciab004).
- 394 13. Clapham H, Hay J, Routledge I, Takahashi S, Choisy M, Cummings D, et al. Seroepidemiologic
395 study designs for determining SARS-COV-2 transmission and immunity. Emerg Infect Dis. 2020; 26:
396 1978–1986. doi: [10.3201/eid2609.201840](https://doi.org/10.3201/eid2609.201840).
- 397 14. Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, et al. Orthogonal
398 SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable
399 humoral immunity. Immunity. 2020; 53: 925–933.e4. doi: [10.1016/j.immuni.2020.10.004](https://doi.org/10.1016/j.immuni.2020.10.004).
- 400 15. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment
401 of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26: 1200–1204. doi: [10.1038/s41591-020-0965-6](https://doi.org/10.1038/s41591-020-0965-6).
- 402
- 403 16. Ibarondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid
404 decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383: 1085–
405 1087. doi: [10.1056/NEJMc2025179](https://doi.org/10.1056/NEJMc2025179).
- 406 17. Van Elslande J, Oyaert M, Ailliet S, Van Ranst M, Lorent N, Vande Weygaerde Y, et al.
407 Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to
408 eight months after infection. J Clin Virol. 2021; 136: 104765. doi: [10.1016/j.jcv.2021.104765](https://doi.org/10.1016/j.jcv.2021.104765).
- 409 18. L'Huillier AG, Meyer B, Andrey DO, Arm-Vernez I, Baggio S, Didierlaurent A, et al. Antibody
410 persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a
411 prospective longitudinal study. Clin Microbiol Infect. 2021; 27: 784.e1–784.e8. doi:
412 [10.1016/j.cmi.2021.01.005](https://doi.org/10.1016/j.cmi.2021.01.005).
- 413 19. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-
414 CoV-2 assessed for up to 8 months after infection. Science. 2021; 371. doi: [10.1126/science.abf4063](https://doi.org/10.1126/science.abf4063).
- 415 20. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing
416 antibodies to SARS-CoV-2 infection persist for months. Science. 2020; 370: 1227–1230. doi:
417 [10.1126/science.abd7728](https://doi.org/10.1126/science.abd7728).
- 418 21. Tunheim G, Laake I, Robertson AH, Waalen K, Hungnes O, Naess LM, et al. Antibody levels in
419 a cohort of pregnant women after the 2009 influenza A(H1N1) pandemic: waning and association

- 420 with self-reported severity and duration of illness. *Influ Other Respir Viruses*. 2019;13: 191-200. doi:
421 [10.1111/irv.12623](https://doi.org/10.1111/irv.12623).
- 422 22. Abrahamsen R, Fell AK, Svendsen MV, Andersson E, Torén K, Henneberger PK, et al.
423 Association of respiratory symptoms and asthma with occupational exposures: findings from a
424 population-based cross-sectional survey in Telemark, Norway. *BMJ Open*. 2017; 7: e014018. doi:
425 [10.1136/bmjopen-2016-014018](https://doi.org/10.1136/bmjopen-2016-014018).
- 426 23. Caspersen IH, Magnus P, Trogstad L. Excess risk and clusters of symptoms after COVID-19 in a
427 large Norwegian cohort. medRxiv: 2021:2021.10.15.21265038. doi: [10.1101/2021.10.15.21265038](https://doi.org/10.1101/2021.10.15.21265038).
- 428 24. Trogstad L, Robertson AH, Mjaaland S, Magnus P. Association between ChAdOx1 nCoV-19
429 vaccination and bleeding episodes: large population-based cohort study. *Vaccine*. 2021; 39: 5854-
430 5857. doi: [10.1016/j.vaccine.2021.08.055](https://doi.org/10.1016/j.vaccine.2021.08.055).
- 431 25. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. SARS-CoV-2 infection rates
432 of antibody-positive compared with antibody-negative health-care workers in England: a large,
433 multicentre, prospective cohort study (SIREN). *Lancet*. 2021; 397: 1459-1469. doi: [10.1016/S0140-
434 6736\(21\)00675-9](https://doi.org/10.1016/S0140-6736(21)00675-9).
- 435 26. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al.
436 Humoral immune response to SARS-CoV-2 in Iceland. *N Engl J Med*. 2020; 383: 1724–1734. doi:
437 [10.1056/NEJMoa2026116](https://doi.org/10.1056/NEJMoa2026116).
- 438 27. Alejo JL, Mitchell J, Chang A, Chiang TPY, Massie AB, Segev DL, et al. Prevalence and
439 Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19. *Jama*.
440 2022 Feb 3. doi: [10.1001/jama.2022.1393](https://doi.org/10.1001/jama.2022.1393).
- 441 28. Anichini G, Gandolfo C, Terrosi C, Fabrizi S, Miceli GB, Gori Savellini G, et al. Antibody
442 response to SARS-CoV-2 in infected patients with different clinical outcome. *J Med Virol*.
443 2021;93(4):2548-2552. doi: [10.1002/jmv.26789](https://doi.org/10.1002/jmv.26789)
- 444 29. Noh JY, Kwak JE, Yang JS, Hwang SY, Yoon JG, Seong H, et al. Longitudinal assessment of anti-
445 SARS-CoV-2 immune responses for six months based on the clinical severity of COVID-19. *J Infect Dis*.
446 2021;223:754-763. doi: [10.1093/infdis/jiab124](https://doi.org/10.1093/infdis/jiab124)
- 447 30. Havervall S, Jernbom Falk A, Klingström J, Ng H, Greilert-Norin, N.Gabrielsson et al.
448 SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild
449 COVID-19 infection. *PLOS ONE*. 2022; 17: e0262169. doi: [10.1371/journal.pone.0262169](https://doi.org/10.1371/journal.pone.0262169).
- 450
- 451 31. Manisty C, Treibel TA, Jensen M, Semper A, Joy G, Gupta RK, et al. Time series analysis and
452 mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-
453 2 infection. *EBioMedicine*. 2021;65:103259. doi: [10.1016/j.ebiom.2021.103259](https://doi.org/10.1016/j.ebiom.2021.103259).
- 454 32. Van Elslande J, Oyaert M, Ailliet S, Van Ranst M, Lorent N, Vande Weygaerde Y, et al.
455 Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to
456 eight months after infection. *J Clin Virol*. 2021;136:104765. doi: [10.1016/j.jcv.2021.104765](https://doi.org/10.1016/j.jcv.2021.104765).
- 457 33. Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, Le Bert N, et al. Dynamics of SARS-CoV-2
458 neutralising antibody responses and duration of immunity: a longitudinal study. *Lancet Microbe*.
459 2021; 2: e240–e249. doi: [10.1016/S2666-5247\(21\)00025-2](https://doi.org/10.1016/S2666-5247(21)00025-2).
- 460 34. Blomberg B, Mohn KG, Brokstad KA, Zhou F, Linchausen DW, Hansen BA, et al. Long COVID in
461 a prospective cohort of home-isolated patients. *Nature medicine*. 2021; 27: 1607–1613. doi:
462 [10.1038/s41591-021-01433-3](https://doi.org/10.1038/s41591-021-01433-3).
- 463 35. Nilles EJ, Siddiqui SM, Fischinger S, Bartsch YC, de St Aubin M, Zhou G, et al. Epidemiological
464 and Immunological Features of Obesity and SARS-CoV-2. *Viruses*. 2021;13. doi: [10.3390/v13112235](https://doi.org/10.3390/v13112235).
- 465 36. Soffer S, Glicksberg BS, Zimlichman E, Efros O, Levin MA, Freeman R, et al. The association
466 between obesity and peak antibody titer response in COVID-19 infection. *Obesity (Silver Spring)*.
467 2021;29(9):1547-1553. doi: [10.1002/oby.23208](https://doi.org/10.1002/oby.23208).
- 468 37. Ozgocer T, Dagli ŞN, Ceylan MR, Disli F, Ucar C, Yildiz S, et al. Analysis of long-term antibody
469 response in COVID-19 patients by symptoms grade, gender, age, BMI, and medication. *J Med Virol*.
470 2021. doi: [10.1002/jmv.27452](https://doi.org/10.1002/jmv.27452).

- 471 38. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and
472 meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021;21:855. doi: [10.1186/s12879-](https://doi.org/10.1186/s12879-021-06536-3)
473 [021-06536-3](https://doi.org/10.1186/s12879-021-06536-3).
- 474 39. Torén K, Brisman J, Järholm B. Asthma and asthma-like symptoms in adults assessed by
475 questionnaires. A literature review. Chest. 1993;104(2):600-8.
- 476 40. Ong DSY, Fragkou PC, Schweitzer VA, Chemaly RF, Moschopoulos CD, Skevaki Cea. How to
477 interpret and use COVID-19 serology and immunology tests. Clin Microbiol Infect. 2021;27:981-6. doi:
478 [10.1016/j.cmi.2021.05.001](https://doi.org/10.1016/j.cmi.2021.05.001).
- 479 41. Goletti D, Petrone L, Manissero D, Bertolotti A, Rao S, Ndunda N, et al. The potential clinical
480 utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. Clin
481 Microbiol Infect. 2021;27:1784-9. doi: [10.1016/j.cmi.2021.07.005](https://doi.org/10.1016/j.cmi.2021.07.005).
- 482 42. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T Cell
483 Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183(1):158-
484 68.e14. doi: [10.1016/j.cell.2020.08.017](https://doi.org/10.1016/j.cell.2020.08.017)

485

486 **Supporting information**

487

488 **S1 Table. Questions from the questionnaire concerning demographic data, hospitalisation,**
489 **comorbidities, symptoms and fatigue.**

490

491 **S2 Table. The median time between positive PCR and antibody measurements.** The median time
492 between positive PCR and T1 antibody measurement was 127 days (91-153) and between positive
493 PCR and T2 antibody 310 days (291-329). Among the PCR negative participants, the median time
494 between PCR test and T1 total antibody was 200 days (114-217).

495 **Authors' contributions**

496 **Conceptualization:** Anne Kristin Møller Fell, Hege Kersten, Randi Eikeland, Yngvar Tveten,
497 **Carina Thilesen, Marjut Sarjomaa, Neil Pearce, Jan Paul Vandenbroucke**

498 **Data Curation:** Anne Kristin Møller Fell, Marjut Sarjomaa, Harald Reiso, Kristine Karlsrud Berg

499 **Formal Analysis:** Lien my Diep, Chi Zhang

500 **Funding Acquisition:** Anne Kristin Møller Fell, Marjut Sarjomaa

501 **Investigation:** Marjut Sarjomaa, Randi Eikeland, Kristine Karlsrud Berg, Harald Reiso, Yngvar
502 **Tveten, Carina Thilesen**

503 **Methodology:** Anne Kristin Møller Fell, Neil Pearce, Jan Paul Vandenbroucke

504 **Project Administration:** Anne Kristin Møller Fell

505 **Resources:** Marjut Sarjomaa, Yngvar Tveten, Randi Eikeland, Carina Thilesen, Kristine Karlsrud
506 **Berg, Svein Arne Nordbø**

507 **Supervision:** Anne Kristin Møller Fell, Hege Kersten, Yngvar Tveten

508 **Validation:** All authors

509 **Visualization: Anne Kristin Møller Fell, Marjut Sarjoomaa, Randi Eikeland**

510 **Writing – Original Draft Preparation: Marjut Sarjoomaa, Anne Kristin Møller Fell**

511 **Writing – Review & Editing: All authors**

512

513

514




Fig1.